6-[Fluorine-18]Fluorodopamine pharmacokinetics and dosimetry in humans
- National Institutes of Health, Bethesda, MD (United States)
PET scanning after injection of 6-[{sup 18}F]fluorodopamine visualizes tissue sympathetic innervation. Organ dosimetric estimates for 6-[{sup 18}F]fluorodopamine have relied on studies of rats and dogs and on literature about the fate of other radiolabeled catecholamines. This report uses empirical clinical findings in healthy volunteers to refine and extend these estimates. Thoracic PET scanning was conducted and arterial blood and urine samples were obtained after intravenous injection of 6-[{sup 18}F]fluorodopamine into 10 normal volunteers. The main target organs for 6-[{sup 18}F]fluorodopamine-derived radioactivity were the wall of the urinary bladder (3.3 rem for a 4-mCi dose and 3.31-hr voiding interval) and the kidneys (2.9 rem for a 4-mCi dose) due to urinary excretion of radioactive metabolites of [{sup 18}F]-6F-DA. The estimates were about one-fourth those predicted from studies of laboratory animals. At administered doses required to visualize the left ventricular myocardium in humans, a 6-[{sup 18}F]fluorodopamine injection produces acceptable absorbed radiation doses, with the highest doses to the urinary collecting system. 22 refs., 2 figs., 5 tabs.
- OSTI ID:
- 96083
- Journal Information:
- Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: 6 Vol. 35; ISSN 0161-5505; ISSN JNMEAQ
- Country of Publication:
- United States
- Language:
- English
Similar Records
Positron emission tomographic imaging of cardiac sympathetic innervation and function
Fate of tritiated 6-fluorodopamine in rats: A false neurotransmitter for positron emission tomographic imaging of sympathetic innervation and function